Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares
Source: Streetwise Reports  (8/16/19)
Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. More >

InMode Reports Solid Q2 Earnings and Appoints Paula Abdul as Brand Ambassador
Source: Streetwise Reports  (8/14/19)
InMode Ltd. reported Q2/19 earnings and announced that international pop superstar Paula Abdul will be its brand ambassador sending shares "Straight Up" 15% as investors "Rush Rush" to purchase shares today. More >

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results
Source: Streetwise Reports  (8/13/19)
Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. More >

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'
Source: Streetwise Reports  (8/12/19)
The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. More >

Amgen Shares React Favorably to Enbrel Patent Case Victory
Source: Streetwise Reports  (8/12/19)
Amgen shares are trading 5–6% higher today on news that the company has won its Enbrel (etanercept) patent court case. More >

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales
Source: Streetwise Reports  (8/9/19)
Shares in Puma Biotechnology are trading 20% higher today after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. More >

Avedro Shares Looking Up 35% with Glaukos Merger
Source: Streetwise Reports  (8/8/19)
Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. More >

Guardant Health Reports Quarterly Revenue Up 178%
Source: Streetwise Reports  (8/7/19)
Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180–190 million. More >

Allakos Shares Double on AK002 Phase 2 Results and Earnings
Source: Streetwise Reports  (8/5/19)
Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. More >

Biotech 'Thinking Several Steps Ahead with Optimizing IVR Quality Control'
Source: Streetwise Reports  (8/2/19)
The company's latest science, presented at a recent conference, is discussed in a ROTH Capital Partners report. More >

Biotech's Mosquito Test 'Gains Market Acceptance'
Source: Streetwise Reports  (8/2/19)
This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report. More >

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide
Source: Streetwise Reports  (8/2/19)
Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. More >

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months
Source: Peter Epstein for Streetwise Reports  (8/1/19)
Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange. More >

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%
Source: Streetwise Reports  (8/1/19)
Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. More >

EMA Opinion Bodes Well for Biopharma's Drug Getting Orphan Status
Source: Streetwise Reports  (7/31/19)
The designation, opinion and asset are discussed in a ROTH Capital Partners report. More >

Firm's Cannabis Flower Yield Surpasses Expectations
Source: Streetwise Reports  (7/29/19)
Also, the company begins growing a second strain. More >

Mylan Gets a Shot in the Arm with Pfizer Merger Deal
Source: Streetwise Reports  (7/29/19)
EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. More >

Catasys: This Is Bigger Than You Think
Source: Daniel Carlson for Streetwise Reports  (7/26/19)
Daniel Carlson of Tailwinds Research examines the "blockbuster" implications of a recent announcement about this company's OnTrak program. More >

eHealth Shares Up 25% as Quarterly Revenue Doubled and 2019 Guidance Raised
Source: Streetwise Reports  (7/26/19)
The prognosis for online exchange operator eHealth Inc. looks positive as the company reported a 101% increase in Q2/19 revenues over the prior year period and raised full year 2019 revenue estimates by $50 million to $365–385 million, compared with previous guidance of $315–335 million for 2019. More >

Align Technology Reports Strong Q2 Growth but China Sales Worries Leave Investors Frowning
Source: Streetwise Reports  (7/25/19)
Orthodontic and GP Dental medical device maker Align Technology announced a 24.6% increase in sales volume of its Invisalign products in its Q2/19 earnings report, but investors are not smiling much over China growth concerns as the shares of the company have fallen more than 25%. More >

Anixa Licenses Another Potential Blockbuster
Source: Daniel Carlson for Streetwise Reports  (7/24/19)
Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year. More >

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report
Source: Streetwise Reports  (7/24/19)
Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. More >

Biotech Firm ''Creating Innovative Solutions' for Female Health
Source: Streetwise Reports  (7/23/19)
The company's most advanced assets are discussed in a Dawson James Securities report. More >

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'
Source: Streetwise Reports  (7/23/19)
The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. More >

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'
Source: Streetwise Reports  (7/23/19)
The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report. More >